What is the recommended management and prognosis for lung squamous cell carcinoma involving the pleura?

Squamous Cell Lung Cancer with Pleural Involvement: Management and Prognosis

Squamous cell lung cancer involving the pleura represents advanced stage disease (M1a for isolated pleural metastasis) with significantly worse prognosis, requiring systemic therapy as the primary treatment approach, with surgical resection considered only after effective conversion therapy in highly selected cases.

Staging and Prognostic Implications

When squamous cell lung cancer involves the pleura, this fundamentally changes the disease stage and treatment paradigm:

• Isolated pleural metastasis classifies as M1a disease (Stage IV)
• Median survival for pleural carcinosis with malignant pleural effusion is less than 12 months 1
• Squamous histology is an independent poor prognostic factor compared to adenocarcinoma (HR = 1.68, p = 0.012) 2
• Pleural metastasis is one of the most common metastatic sites in squamous NSCLC, occurring more frequently than brain metastasis 3

Primary Treatment Approach: Systemic Therapy

First-Line Treatment Selection Based on PD-L1 Status

For PD-L1 TPS ≥50% (High Expression):

The optimal approach remains debated between monotherapy immunotherapy and chemoimmunotherapy. Based on the most recent evidence 4:

• Pembrolizumab monotherapy shows strong efficacy with PFS HR of 0.437 (95% CI, 0.321-0.594) in squamous patients
• Chemoimmunotherapy (pembrolizumab + carboplatin-paclitaxel) demonstrates PFS HR of 0.37 (95% CI, 0.24-0.58) in the TPS ≥50% squamous subset 4
• Cemiplimab plus chemotherapy achieved median OS of 22.2 months versus 15.1 months with chemotherapy alone (HR 0.77) in squamous patients with PD-L1 ≥50% 4

Choose chemoimmunotherapy over monotherapy if the patient is symptomatic from disease burden, as it provides faster disease control 4.

For PD-L1 TPS <50%:

• Platinum-based doublet chemotherapy combined with PD-(L)1 checkpoint inhibitors is the standard approach 4, 5
• Paclitaxel-based regimens combined with PD-(L)1 inhibitors show superior outcomes (SUCRA: 96.52% for PFS, 83.58% for OS) 5
• The KEYNOTE-407 trial specifically enrolled squamous histology patients and demonstrated significant PFS and OS improvements with pembrolizumab plus chemotherapy across all PD-L1 levels 4

Surgical Consideration After Conversion Therapy

Surgery should only be considered after effective conversion therapy in highly selected patients with isolated pleural metastasis 2. This represents a paradigm shift from traditional palliative-only approaches.

Criteria for Surgical Candidacy:

1. Response to conversion therapy: PR/CR (not SD) - SD is an independent risk factor for worse OS (HR = 1.82, p = 0.006) 2
2. Driver gene status: Presence of targetable mutations improves outcomes (driver gene negativity: HR = 1.61, p = 0.024) 2
3. Nodal status: N0-N1 disease (N2 involvement: HR = 1.85, p = 0.003) 2
4. Technical feasibility: Ability to achieve R0 resection (non-R0: HR = 2.08, p = 0.001) 2

Outcomes After Surgical Resection:

Among 167 patients who underwent surgery after conversion therapy 2:

• Median OS: 22.6 months (95% CI: 18.4-26.8)
• Median PFS: 12.4 months (95% CI: 9.2-15.6)
• 1-year survival: 89.7%
• 2-year survival: 42.1%
• Postoperative complication rate: 12.57%, with major complications (Clavien-Dindo ≥3) in 28.57% of those with complications

Critical caveat: Squamous histology remains an independent poor prognostic factor even after surgical resection (HR = 1.68) compared to adenocarcinoma 2.

Management of Malignant Pleural Effusion

For symptomatic pleural effusion causing dyspnea, palliative interventions are essential 1:

• Thoracocentesis for immediate symptom relief
• Permanent pleural catheters versus talcum pleurodesis - the only randomized trial showed comparable efficacy 1
• Choose permanent catheters for patients with limited life expectancy or trapped lung
• Choose pleurodesis for patients with good performance status and expandable lung

Treatment Algorithm

1. Confirm diagnosis: Ensure this is primary lung squamous cell carcinoma, not metastatic squamous carcinoma from another site (cutaneous, head/neck, urothelial, thymic) - misdiagnosis occurs in 3.1% of cases 6

2. Assess PD-L1 status and driver mutations (though rare in squamous histology)

3. Initiate systemic therapy:

   • PD-L1 ≥50% + symptomatic: Paclitaxel-based chemotherapy + pembrolizumab
   • PD-L1 ≥50% + asymptomatic: Consider pembrolizumab monotherapy
   • PD-L1 <50%: Paclitaxel-based chemotherapy + PD-(L)1 inhibitor

4. Manage pleural effusion if symptomatic with drainage ± pleurodesis

5. After 4-6 cycles: MDT assessment for surgical candidacy if:

   • PR/CR achieved
   • Isolated pleural disease
   • N0-N1 status
   • R0 resection feasible
   • Patient has adequate performance status

6. If not surgical candidate: Continue maintenance therapy or observation based on response

Key Prognostic Factors to Monitor

Independent predictors of worse overall survival 2:

• Squamous histology (vs. adenocarcinoma)
• Driver gene negativity
• SD response to conversion therapy
• N2 lymph node involvement
• Non-R0 resection
• Bone metastasis 3
• Male sex, liver metastasis 3

The presence of pleural involvement fundamentally indicates advanced disease requiring systemic therapy as the cornerstone of treatment, with surgery reserved only for exceptional responders to conversion therapy who meet strict selection criteria.